fam172a Antibody

What is FAM172A and what are its main cellular functions?

FAM172A (Family with sequence similarity 172 member A) is a protein implicated in several critical cellular processes. It primarily functions as a regulator of AGO2 nuclear localization in mammalian cells, with research showing that FAM172A loss causes AGO2 to become markedly enriched in the cytoplasm rather than the nucleus . Additionally, FAM172A has been associated with endoplasmic reticulum (ER) stress responses and cell proliferation pathways . It demonstrates regulatory effects on the autophagy process in fibroblasts, where overexpression of FAM172A results in decreased expression of autophagy marker proteins like LC3-II, Beclin-1, and ATG-5 . FAM172A also influences apoptotic pathways by inhibiting the expression of apoptosis-promoting protein Bax while promoting expression of apoptosis-inhibiting protein Bcl-2 . Recent studies further suggest its involvement in epidural fibrosis suppression, demonstrating its multi-functional nature in cellular regulation .

What types of FAM172A antibodies are available for research applications?

Based on the research literature, several types of FAM172A antibodies have been developed and utilized in experimental settings:

• Polyclonal antibodies: Rabbit polyclonal antibodies against FAM172A have been successfully generated and used in multiple research applications. These are produced by immunizing rabbits with FAM172A recombinant protein (particularly the FAM172A-3 variant), followed by purification using Protein A Sepharose columns .

• Commercial antibodies: The literature references commercially available polyclonal antibodies (such as ab121364 from Abcam) that can detect multiple FAM172A isoforms .

• Isoform-specific antibodies: Given that FAM172A exists in multiple isoforms (371aa, 417aa, and 307aa in mice), some antibodies can recognize all isoforms while others might be more specific to particular variants .

These antibodies have been validated for use in western blot analysis, immunofluorescence, co-immunoprecipitation, and other standard protein detection techniques .

What are the recommended methods for validating FAM172A antibody specificity?

Validating FAM172A antibody specificity is crucial for ensuring reliable experimental results. Based on established protocols in the literature, researchers should:

• Perform western blot analysis using both wild-type and FAM172A-knockout or knockdown samples. In properly validated antibodies, bands corresponding to FAM172A should be absent or significantly reduced in knockout/knockdown samples .

• Test multiple isoforms: Since FAM172A exists in different isoforms (in mice: 371aa, 417aa, and 307aa), antibody validation should confirm which isoforms are detectable with the specific antibody. Research has shown that the 371aa isoform is predominant in most murine tissues and cell lines .

• Conduct ELISA testing: For quantitative validation of antibody binding capacity and specificity .

• Verify using different techniques: Cross-validate antibody specificity using complementary techniques such as immunofluorescence, western blot, and immunoprecipitation to ensure consistent detection patterns .

• Include appropriate controls: Use pre-immune serum as a negative control and recombinant FAM172A protein as a positive control to establish specificity boundaries .

These validation steps should be performed before applying the antibody to experimental research to ensure accurate and reproducible results.

What are the optimal conditions for using FAM172A antibodies in western blot applications?

For optimal western blot detection of FAM172A, researchers should consider the following protocol parameters based on successful applications in the literature:

• Protein extraction and loading:

  • Use Mem-PER mammalian protein extraction reagent with protease inhibitors for cell lysis

  • Load approximately 50 μg protein per lane

  • Include appropriate controls (β-Actin or GAPDH)

• SDS-PAGE conditions:

  • Use standard SDS-PAGE separation

  • For mouse FAM172A detection, expect bands at approximately:

    • 371aa isoform (predominant)

    • 417aa isoform (weakly expressed)

    • 307aa isoform (often undetectable)

• Transfer and blocking:

  • Transfer proteins to nitrocellulose membranes

  • Block membranes in 5% nonfat dried milk or 5% bovine serum albumin in buffer saline for 1 hour at room temperature

• Antibody incubation:

  • Primary antibody incubation: overnight at 4°C (concentration optimized for specific antibody, typically 1:1000 to 1:2000)

  • Secondary antibody incubation: 1 hour at room temperature

  • Wash 3 times with PBS between incubations

• Detection:

  • Visualize with enhanced chemiluminescent reagents

  • For studies involving nuclear vs. cytoplasmic distribution, cellular fractionation prior to western blot is recommended

These conditions have been successfully employed in multiple studies examining FAM172A expression and function.

How can FAM172A antibodies be used to investigate AGO2 nuclear localization mechanisms?

FAM172A antibodies are instrumental in elucidating the mechanisms of AGO2 nuclear localization through several advanced experimental approaches:

These approaches have collectively demonstrated that FAM172A functions as a nuclear import factor for AGO2 through its bipartite NLS, and this mechanism is disrupted in CHARGE syndrome-associated mutations.

What are the challenges in detecting different FAM172A isoforms, and how can antibody-based approaches address them?

Detecting different FAM172A isoforms presents several challenges that can be addressed through optimized antibody-based approaches:

Challenges:

• Multiple isoform expression: The Ensembl genome browser predicts three major FAM172A isoforms in mice (371aa, 417aa, and 307aa), with varying expression levels across tissues and developmental stages .

• Isoform-specific functions: Different isoforms may have distinct functions or subcellular localizations.

• Cross-reactivity concerns: Standard antibodies may not distinguish between closely related isoforms.

• Low expression levels: Some isoforms (particularly the 307aa variant) may be expressed at levels below detection thresholds .

Antibody-based solutions:

• Isoform mapping and epitope analysis: Carefully select antibodies based on epitope locations that can distinguish between isoforms. Commercial polyclonal antibodies like ab121364 (Abcam) can detect multiple FAM172A isoforms .

• Combined detection approaches:

  • Western blot analysis using gradient gels to resolve closely sized isoforms

  • RT-PCR to correlate protein detection with transcript expression

  • Immunoprecipitation followed by mass spectrometry for isoform identification

• Developmental profiling: As demonstrated in murine studies, examining FAM172A expression across developmental stages (e9.5 to e15.5) can help establish isoform prevalence patterns. This approach has revealed that the 371aa isoform is predominant in multiple cell lines including Neuro2a neuroblasts, NIH 3T3 fibroblasts, and R1 embryonic stem cells .

• Isoform-specific antibody generation: When necessary, developing antibodies targeting unique regions of specific isoforms can help differentiate their expression and localization patterns.

Through these approaches, researchers can overcome the challenges associated with detecting and distinguishing multiple FAM172A isoforms.

How can phosphorylation status of FAM172A be analyzed using specialized antibody techniques?

The phosphorylation status of FAM172A, particularly at CK2-targeted sites, can be analyzed using specialized antibody techniques:

Research has shown that phosphorylation of FAM172A may influence its nuclear localization signal (NLS) recognition by importins, thereby regulating its role in AGO2 nuclear translocation . These specialized antibody techniques provide valuable tools for investigating this regulatory mechanism.

What considerations are important when using FAM172A antibodies to study protein-protein interactions?

When using FAM172A antibodies to study protein-protein interactions, several important considerations should be addressed:

• Antibody concentration optimization: Determining the optimal antibody concentration is crucial for co-immunoprecipitation experiments. Studies have shown that 5 μg/mL may be the optimal concentration for FAM172A antibodies in co-IP applications, yielding better results than lower (2 μg/mL) or higher (10 μg/mL) concentrations .

• Subcellular fraction selection: Since FAM172A interacts with different proteins in different cellular compartments, selecting the appropriate cellular fraction is important:

  • For membrane protein interactions, proper membrane protein isolation methods should be employed

  • For nuclear interactions (such as with AGO2), nuclear extraction protocols are essential

• Confirmation of direct interactions: Using purified proteins for in vitro co-IP assays can help determine if FAM172A interactions are direct or mediated by other proteins. This approach confirmed the direct interaction between FAM172A and AGO2 .

• Domain-specific interactions: Using truncated or mutated versions of FAM172A can identify specific domains responsible for protein interactions. For example, the E229 residue of FAM172A is critical for its interaction with AGO2's PAZ domain-containing region .

• Validation with multiple techniques: Findings from co-IP should be validated using complementary approaches:

  • Bimolecular fluorescence complementation (BiFC)

  • Proximity ligation assays

  • Confocal microscopy for co-localization studies

Research has identified several potential FAM172A-interacting proteins, including seven membrane proteins (MACF, PTPRF, NDST, SLC27A6, ACVRL1, RAB27A, and RAB3D) and twelve non-membrane proteins involved in various cellular functions . These interactions suggest FAM172A may function in multiple signaling pathways including MAPK/ERK and PI3K/Akt .

What are common technical challenges when using FAM172A antibodies, and how can they be resolved?

Researchers working with FAM172A antibodies may encounter several technical challenges that can be addressed through specific methodological modifications:

Challenge 1: Background or non-specific binding

• Solution: Optimize blocking conditions using 5% BSA or 5% nonfat dried milk in buffer saline for 1 hour at room temperature

• Additional steps: Pre-absorb antibodies with cell lysates from FAM172A-knockout cells to reduce non-specific binding

• Control measure: Always include normal IgG controls in immunoprecipitation experiments to identify non-specific bands

Challenge 2: Detecting low-abundance isoforms

• Solution: Use enrichment techniques such as immunoprecipitation before western blot

• Alternative approach: Increase protein loading (up to 100 μg) for detecting minor isoforms like the 417aa variant

• Verification method: Combine with RT-PCR to confirm expression at the mRNA level

Challenge 3: Nuclear vs. cytoplasmic distribution analysis

• Solution: Employ rigorous cell fractionation protocols with multiple washing steps

• Validation approach: Use leptomycin B (LMB) treatment to block nuclear export for clearer visualization of nuclear localization patterns

• Control markers: Include nuclear (e.g., lamin B) and cytoplasmic (e.g., GAPDH) markers to confirm fraction purity

Challenge 4: Phosphorylation-dependent epitope masking

• Solution: Test antibody detection under various phosphatase treatment conditions

• Alternative approach: Use multiple antibodies targeting different epitopes of FAM172A

• Consideration: Interpret results in light of known phosphorylation sites (S217 and S218 in mice)

Challenge 5: Cross-reactivity with related proteins

• Solution: Validate specificity using FAM172A-knockout or knockdown samples

• Additional control: Perform peptide competition assays to confirm epitope specificity

• Verification method: Compare detection patterns across multiple antibodies targeting different epitopes

These troubleshooting approaches can help researchers overcome common technical challenges and obtain more reliable results when working with FAM172A antibodies.

How should researchers interpret apparently contradictory results when using FAM172A antibodies in different cell types?

When confronted with seemingly contradictory results using FAM172A antibodies across different cell types, researchers should consider several interpretive frameworks:

• Cell type-specific expression patterns:

  • FAM172A expression varies across cell types and developmental stages

  • The predominant isoform (371aa in murine cells) is consistently detected, while minor isoforms (417aa and 307aa) show variable expression

  • Create a comparative expression table across cell types to identify patterns:

  Cell Type	Predominant Isoform	Secondary Isoforms	Subcellular Localization
  MEFs	371aa	Weak 417aa	Nuclear
  Neuro2a	371aa	Weak 417aa	Nuclear
  NIH 3T3	371aa	Weak 417aa	Nuclear
  R1 ES Cells	371aa	Weak 417aa	Nuclear
  Fibroblasts (FT)	Not specified	Not specified	Nuclear with functional role in autophagy
  Epidural Scar Tissue (ST)	Not specified	Not specified	Nuclear with enhanced role in autophagy

• Context-dependent protein interactions:

  • FAM172A interacts differently with partners depending on cellular context

  • In MEFs, FAM172A primarily regulates AGO2 nuclear localization

  • In fibroblasts, it modulates autophagy marker proteins (LC3-II, Beclin-1, ATG-5)

  • In HepG2 cells, it influences proliferation through potential interactions with membrane proteins

• Methodological considerations:

  • Different lysis conditions may extract FAM172A with varying efficiency

  • Nuclear extraction protocols should be optimized for each cell type

  • Membrane protein isolation requires specialized techniques that may yield different results across cell types

• Mutation and phosphorylation effects:

  • E229Q mutation increases FAM172A nuclear localization while disrupting AGO2 interaction

  • Phosphorylation at S217/S218 may regulate function differently across cell types

  • Consider phosphatase treatment to normalize phosphorylation status when comparing results

• Experimental design reconciliation strategy:

  • Perform side-by-side comparisons using identical protocols across cell types

  • Include positive controls (recombinant FAM172A) for antibody validation

  • Consider co-expression of interacting partners (e.g., AGO2) that may influence detection patterns

By systematically addressing these factors, researchers can reconcile apparently contradictory results and develop a more comprehensive understanding of FAM172A biology across different cellular contexts.

What controls should be included when using FAM172A antibodies for immunofluorescence studies?

For robust immunofluorescence studies using FAM172A antibodies, a comprehensive set of controls should be implemented:

• Primary antibody controls:

  • Negative control: Omit primary antibody but include secondary antibody to assess background fluorescence

  • Isotype control: Use non-specific IgG from the same species as the FAM172A antibody

  • Peptide competition: Pre-incubate antibody with excess FAM172A recombinant protein to confirm signal specificity

  • Concentration gradient: Test multiple antibody dilutions to determine optimal signal-to-noise ratio

• Genetic validation controls:

  • FAM172A-knockout or knockdown cells: Should show significantly reduced or absent signal compared to wild-type cells

  • Overexpression control: Cells transfected with FAM172A expression vectors should show increased signal intensity

  • Mutant controls: Cells expressing E229Q-mutated FAM172A show altered nuclear localization patterns that can serve as specificity controls

• Subcellular localization controls:

  • Nuclear marker: Co-stain with DAPI or other nuclear markers to confirm nuclear localization

  • Nuclear export inhibition: Leptomycin B (LMB) treatment can enhance nuclear signal by blocking nuclear export

  • Subcellular fractionation validation: Compare immunofluorescence results with biochemical fractionation data

• Functional validation controls:

  • AGO2 co-localization: In studies of FAM172A-AGO2 interaction, co-staining should show expected co-localization patterns

  • NLS mutation control: FAM172A with mutated nuclear localization signal shows altered localization pattern

  • Importin inhibition: Treatment with importin inhibitors (e.g., ivermectin) should alter FAM172A nuclear localization pattern

• Technical controls:

  • Fixation method comparison: Compare paraformaldehyde, methanol, and other fixation methods to ensure optimal epitope preservation

  • Permeabilization optimization: Test different permeabilization agents (Triton X-100, saponin) to ensure antibody access

  • Multi-channel controls: For co-localization studies, include single-labeled samples to confirm lack of channel bleed-through

Implementation of these controls ensures reliable and interpretable immunofluorescence results when studying FAM172A localization and function.

How can FAM172A antibodies be utilized to investigate its role in ER stress and autophagy?

FAM172A antibodies can be strategically employed to investigate its role in ER stress and autophagy through several experimental approaches:

• Monitoring FAM172A dynamics during ER stress:

  • Use western blot with FAM172A antibodies to track protein levels after treatment with ER stress inducers (thapsigargin, tunicamycin, etc.)

  • Compare FAM172A subcellular distribution before and during ER stress using immunofluorescence

  • Perform co-immunoprecipitation to identify stress-specific interaction partners

• FAM172A-autophagy pathway analysis:

  • Correlate FAM172A levels with autophagy markers (LC3-II, Beclin-1, ATG-5, p62) under various conditions

  • The research demonstrates that FAM172A overexpression decreases expression of autophagy markers, while FAM172A knockdown increases their expression

  • Use dual immunofluorescence with FAM172A antibodies and autophagosome markers to visualize potential co-localization

• Intervention studies:

  • After FAM172A overexpression or knockdown, use FAM172A antibodies to confirm intervention success

  • Measure corresponding changes in:

    • Autophagy marker proteins (LC3-II conversion, Beclin-1, ATG-5, p62)

    • Apoptosis regulators (Bax, Bcl-2)

    • ER stress markers (BiP/GRP78, CHOP, XBP1 splicing)

• Tissue-specific analysis:

  • Apply FAM172A antibodies in immunohistochemistry to examine expression in normal fibrosis tissue (FT) versus scar tissue (ST)

  • Correlate with autophagy and ER stress markers in animal models of fibrosis

  • Research shows FAM172A overexpression reduces fibrosis and scar tissue formation in laminectomy models

• Mechanistic pathway elucidation:

  • Use immunoprecipitation with FAM172A antibodies followed by proteomic analysis to identify:

    • UPR (unfolded protein response) components that interact with FAM172A

    • Autophagy regulatory proteins in the FAM172A interactome

    • Potential post-translational modifications during stress responses

The research evidence indicates that FAM172A functions as a negative regulator of autophagy, where its overexpression suppresses autophagy marker expression and epidural fibrosis formation, while promoting anti-apoptotic protein expression . These methodologies utilizing FAM172A antibodies can further elucidate the molecular mechanisms underlying these observations.

What experimental approaches can determine if FAM172A protein-protein interactions are direct or indirect?

Determining whether FAM172A protein-protein interactions are direct or indirect requires a systematic experimental approach using various antibody-based and complementary techniques:

• In vitro co-immunoprecipitation with purified proteins:

  • Use purified recombinant FAM172A and potential interacting partners

  • Perform co-IP using FAM172A antibodies in a cell-free system

  • This approach successfully confirmed direct interaction between FAM172A and AGO2

  • Advantages: Eliminates cellular factors that might mediate indirect interactions

• Domain mapping with truncated proteins:

  • Generate truncated versions of FAM172A to identify interaction domains

  • Perform co-IP with FAM172A antibodies against each truncated variant

  • Research has shown that the E229 residue of FAM172A is critical for AGO2 interaction

  • Specific binding domains suggest direct interactions

• Bimolecular fluorescence complementation (BiFC):

  • Fuse potential interacting proteins with complementary fragments of fluorescent proteins

  • Direct interactions bring fragments together, generating fluorescence

  • This approach revealed FAM172A-AGO2 interaction dynamics in living cells

  • Advantages: Visualizes interactions in their native cellular context

• Surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC):

  • Measure binding kinetics and thermodynamics between purified FAM172A and partner proteins

  • Advantages: Provides quantitative binding parameters that characterize direct interactions

  • Can determine binding affinity constants (KD) for direct interactions

• Proximity ligation assay (PLA):

  • Uses antibodies against FAM172A and potential partners

  • Generates fluorescent signal only when proteins are within 40 nm of each other

  • Advantages: Higher specificity than co-localization by conventional immunofluorescence

• Pull-down assays with recombinant proteins:

  • Use GST or His-tagged FAM172A to pull down potential partners from cell lysates

  • Analyze interactions by mass spectrometry to identify direct binding partners

  • The research identified seven membrane proteins and twelve non-membrane proteins that may interact with FAM172A

• Cross-linking mass spectrometry:

  • Chemically cross-link protein complexes containing FAM172A

  • Digest and analyze by mass spectrometry to identify cross-linked peptides

  • Advantages: Provides information about interaction interfaces at amino acid resolution

These approaches, particularly when used in combination, can provide strong evidence for determining whether FAM172A protein-protein interactions are direct or indirect, as well as characterizing the molecular details of these interactions.

How can FAM172A antibodies contribute to understanding its role in disease mechanisms?

FAM172A antibodies provide valuable tools for investigating its role in disease mechanisms, particularly in CHARGE syndrome, cancer, and fibrotic disorders:

• CHARGE syndrome investigations:

  • FAM172A antibodies can detect the E228Q variant (E229Q in mice) associated with CHARGE syndrome

  • Immunofluorescence studies reveal that this mutation affects AGO2 nuclear localization while potentially increasing FAM172A nuclear accumulation

  • Co-immunoprecipitation analysis has demonstrated that this mutation disrupts direct interaction with AGO2

  • Research applications include:

    • Screening patient samples for altered FAM172A localization

    • Identifying dysregulated downstream pathways in mutation carriers

    • Testing potential therapeutic approaches that restore proper AGO2 localization

• Cancer research applications:

  • FAM172A antibodies can monitor expression in hepatocellular carcinoma cells, where it influences proliferation

  • Western blot analysis can track activation of:

    • MAPK/ERK signaling pathway components

    • PI3K/Akt signaling pathway proteins

  • Immunohistochemistry can assess FAM172A expression patterns in tumor versus normal tissues

  • The research has identified potential membrane protein interactions (MACF, PTPRF, NDST, SLC27A6, ACVRL1, RAB27A, and RAB3D) that may contribute to proliferation mechanisms

• Fibrotic disorders:

  • FAM172A antibodies can monitor expression changes during fibrotic processes

  • Western blot analysis shows that FAM172A regulates autophagy markers (LC3-II, Beclin-1, ATG-5) and apoptosis regulators (Bax, Bcl-2)

  • Immunohistochemistry in animal models demonstrates FAM172A's role in suppressing epidural fibrosis

  • Research applications include:

    • Monitoring FAM172A expression in fibrotic vs. normal tissues

    • Tracking therapeutic responses to FAM172A-targeted interventions

    • Identifying patient subgroups with altered FAM172A expression or function

• Mechanistic studies in disease models:

  • FAM172A antibodies enable the creation of comprehensive protein interaction networks in disease states

  • Phospho-specific antibodies can detect altered phosphorylation at S217/S218 residues that may occur in pathological conditions

  • Chromatin immunoprecipitation (ChIP) can identify disease-specific alterations in FAM172A-associated gene regulation

These research applications of FAM172A antibodies contribute to a deeper understanding of disease mechanisms and may ultimately lead to the development of targeted therapeutic approaches for conditions involving FAM172A dysregulation.